Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA-a simultaneous study of 130 potentially functional SNPs in 14 candidate genes

Rheumatology

Volumn 51, Issue 5, 2012, Pages 841-851

  Enjuanes, Anna ^a   Benavente, Yolanda ^b,c   Hernández rodríguez, José ^d   Queralt, Carme ^d   Yagüe, Jordi ^a   Jares, Pedro ^a   De sanjosé, Silvia ^b,c   Campo, Elias ^a   Cid, Maria C ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Genetic risk; Genetic variation; Giant cell arteritis; Haplotypes; Single nucleotide polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR7; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; CCL2 GENE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENETIC RISK; GENOTYPE; GIANT CELL ARTERITIS; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INFG GENE; LTA GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CHEMOKINE CCL2; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GIANT CELL ARTERITIS; HAPLOTYPES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860249172     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker429     Document Type: Article

References (52)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
2. Cid MC, Campo E, Ercilla G et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93.
3. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
4. Cid MC, Hoffman MP, Hernandez-Rodriguez J et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology 2006;45:1356-63.
5. Hernandez-Rodriguez J, Segarra M, Vilardell C et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004;43:294-301.
6. Kaiser M, Younge B, Bjornsson J et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999; 155:765-74.
7. Lozano E, Segarra M, Garcia-Martinez A et al. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 2008;67:1581-8.
8. Segarra M, Garcia-Martinez A, Sanchez M et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007;66:1429-35.
9. Hernandez-Rodriguez J, Segarra M, Vilardell C et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
10. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 2010;62:835-41.
11. Wernick R, Davey M, Bonafede P. Familial giant cell arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 1994;12:63-6.
12. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
13. Cid MC, Ercilla G, Vilaseca J et al. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum 1988;31:678-82.
14. Ly KH, Regent A, Tamby MC et al. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev 2010;9:635-45.
15. Martinez-Taboada VM, Alvarez L, RuizSoto M et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-20.
16. Salvarani C, Macchioni P, Zizzi F et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34:351-6.
17. Alvarez-Rodriguez L, Martinez-Taboada VM, Lopez-Hoyos M et al. Interleukin-12 gene polymorphisim in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Clin Exp Rheumatol 2009;27:S14-18.
18. Amoli MM, Gonzalez-Gay MA, Zeggini E et al. Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis. J Rheumatol 2004;31: 2413-7.
19. Boiardi L, Casali B, Farnetti E et al. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum 2006;54:4011-7.
20. Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004;22: S18-20.
21. Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84.
22. Gonzalez-Gay MA, Di Giovine FS, Silvestri T et al. Lack of association between IL-1 cluster and TNF-alpha gene polymorphisms and giant cell arteritis. Clin Exp Rheumatol 2002;20:431.
23. Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004;22: S18-20.
24. Mattey DL, Hajeer AH, Dababneh A et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000;43:1749-55.
25. Rueda B, Roibas B, Martin J et al. Influence of interleukin promoter polymorphisms in susceptibility to giant cell arteritis in northwestern Spain. J Rheumatol 2007;34: 1535-9.
26. Salvarani C, Casali B, Farnetti E et al. Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. J Rheumatol 2005;32:2173-7.
27. Krupa WM, Dewan M, Jeon MS et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002;161:1815-23.
28. Rittner HL, Kaiser M, Brack A et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;84: 1050-8.
29. Weyand CM, Schonberger J, Oppitz U et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994;179:951-60.
30. Conde L, Vaquerizas JM, Ferrer-Costa C et al. PupasView: a visual tool for selecting suitable SNPs, with putative pathological effect in genes, for genotyping purposes. Nucleic Acids Res 2005;33:W501-5.
31. Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
32. The International HapMap Project. Nature 2003;426: 789-96.
33. Wacholder S, Chanock S, Garcia-Closas M et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
34. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-9.
35. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81: 559-75.
36. Cid MC, Font C, Oristrell J et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41: 26-32.
37. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.
38. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol 2010;88: 1157-62.
39. Warpeha KM, Xu W, Liu L et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999;13: 1825-32.
40. Gonzalez-Gay MA, Oliver J, Sanchez E et al. Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2005;32:2178-82.
41. Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
42. Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009;8:2496-508.
43. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-7.
44. Boiardi L, Casali B, Nicoli D et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003;30:2160-4.
45. Huez I, Bornes S, Bresson D et al. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 2001;15:2197-210.
46. Huez I, Creancier L, Audigier S et al. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 1998;18:6178-90.
47. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
48. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994;14:4443-54.
49. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
50. Boiardi L, Casali B, Farnetti E et al. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006;33:703-8.
51. Hacker UT, Erhardt S, Tschop K et al. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination. Clin Exp Immunol 2001;125:465-9.
52. Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M et al. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: association of IL-1RN*2/2 genotype with polymyalgia rheumatica. Hum Immunol 2009;70:49-54.